5 Einträge gefunden

1. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

   1. Vithayathil, Mathew
   2. D'Alessio, Antonio
   3. Fulgenzi, Claudia Angela Maria
   4. Nishida, Naoshi
   5. Schönlein, Martin
   6. von Felden, Johann
   7. Schulze, Kornelius

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

   1. Vithayathil, Mathew
   2. D'Alessio, Antonio
   3. Fulgenzi, Claudia Angela Maria
   4. Nishida, Naoshi
   5. Schönlein, Martin
   6. von Felden, Johann
   7. Schulze, Kornelius

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study

   1. D'Alessio, Antonio
   2. Fulgenzi, Claudia Angela Maria
   3. Nishida, Naoshi
   4. Schönlein, Martin
   5. von Felden, Johann
   6. Schulze, Kornelius
   7. Wege, Henning

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

   1. Fulgenzi, Claudia Angela Maria
   2. Cheon, Jaekyung
   3. D'Alessio, Antonio
   4. Nishida, Naoshi
   5. Ang, Celina
   6. Marron, Thomas U
   7. Wu, Linda

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

   1. Wu, Yue Linda
   2. Fulgenzi, Claudia Angela Maria
   3. D'Alessio, Antonio
   4. Cheon, Jaekyung
   5. Nishida, Naoshi
   6. Saeed, Anwaar
   7. Wietharn, Brooke

   2022 - Forschungsinformationssystem des UKE - frei zugänglich